The Australian Medical Association (AMA) has consistently argued against the removal of the seven-day delay for pathology and diagnostic imaging results in MHR.
The Australian Digital Health Agency (ADHA) has implemented the next phase of the Share by Default reforms to provide consumers with faster access to pathology and diagnostic imaging reports in My Health Record (MHR). Last week the seven-day delay was removed for most pathology tests, with a five-day delay retained for certain tests such as anatomical pathology, cytopathology and genetic tests.
From February 2026, the delay will be removed for x-ray reports of extremities and reduced to five days for other diagnostic imaging reports, including CT, MRI, PET, ultrasound and x-rays of the head and thorax. These changes aim to improve transparency and consumer engagement, while maintaining limited delays for clinically sensitive tests.
The Australian Medical Association (AMA) has consistently argued against the removal of the seven-day delay for pathology and diagnostic imaging results in MHR. Our position, well documented in public submissions, position statements, and media commentary, is grounded in patient safety and continuity of care.
We have commented that immediate access to results without clinical interpretation risks causing unnecessary distress and confusion for patients, particularly when results are complex or abnormal. Doctors should have the opportunity to review and interpret results before patients see them, ensuring patients receive accurate explanations and appropriate follow-up care. Without this safeguard, there is a real risk that patients may misinterpret results, delay necessary treatment, or overwhelm practices with urgent inquiries before clinicians have had time to review the findings.
While we recognise the benefits of patient engagement and transparency, the AMA has advocated for a balanced approach. We acknowledge a panel of clinical and consumer experts has informed the government's decision, with particular attention to tests and scenarios where immediate release could cause harm or distress. We are pleased the government's criteria for retaining a delay to release results are based on the potential for results to cause significant psychological impact, require complex interpretation, or involve vulnerable groups - such as minors, those under guardianship, or individuals undergoing sensitive testing. The changes include exceptions for certain test types, including anatomical pathology, genetics, and some imaging, where specialist input or additional safeguards are necessary to protect patient wellbeing and ensure appropriate clinical follow-up.
The AMA's advocacy has been informed by member feedback, clinical experience, and a commitment to evidence-based policy. We will continue to call for strict protocols, clear communication strategies, and ongoing clinical governance to ensure all changes facilitating faster access don't compromise patient outcomes or place undue burden on clinicians. We remain committed to working with government and stakeholders to monitor the impact of these reforms and to advocate for further improvements where necessary.
